Press Releases

Hi-Tech Signs International Distribution Agreement

Amityville, N.Y. September 5, 2001—Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) announced today that it had signed its first international distribution agreement for its branded products for diabetics. According to the Agreement, Dr. Po Pharmaceuticals in alliance with the Diabetes Association, will market and distribute the DiabetiTussin®, line through its dedicated sales force to doctors, drug stores and hospitals in Taiwan, targeting almost one million people affected with the disease.

Commenting on the Agreement and the first purchase order David Seltzer, President and CEO of Hi-Tech, said: “We are very pleased to announce our first order from Taiwan for DiabetiDermÆ Cream and Lotion indicated for severely dry skin, which is an extremely common complication caused by diabetes. Our partner, Dr. Po Pharmaceuticals, has a solid record of marketing and distributing pharmaceutical products in Taiwan. We hope that these items will be soon followed by other products marketed by the Healthcare Products Division of Hi-Tech, including its leading DiabetiTussinÆ brand of sugar free cough & cold remedies.

We regard this Agreement as the first step in implementing our strategy of penetrating international markets with our products that help people with diabetes live healthier lives. There are 100 million diabetics world wide that creates enormous opportunities for Hi-Tech.”

Hi-Tech is a specialty pharmaceuticals manufacturer and marketer of branded and generic prescription and OTC products for the general healthcare industry. A specialist in liquid and semi-solid dosage form production, Hi-Tech markets a broad line of generic products under its own labels, and also serves as a contract manufacturer to the industry. The company’s Health Care Products division is a leading manufacturer and marketer of branded OTC products for the diabetes marketplace.

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that all forward-looking statements involve risks and uncertainties, including those risks and uncertainties detailed in the Company’s filings with the Securities and Exchange Commission, copies of which are available from the Company.